



Information Disclosure Statement Form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	28575/US/US
-------	---	----	---	------------------------	-------------

### U.S. PUBLISHED DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Kew		US- 2003/0165873	09-04-2003	Come et al.	
		US- 2004/0043388	03-04-2004	Come et al.	
ICW		US- 2004/0122029	06-24-2004	Liu et al.	

### FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
ICW		WO	2004/054617	07-01-2004	Kyowa Hakko Kogyo Co.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/080980	09-23-2004	Novartis A.G.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/074262	09-02-2004	Tibotec Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/074244	09-02-2004	SmithKline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/069812	08-19-2004	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/056786	07-08-2004	Pfizer Products Inc., USA		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/050068	06-17-2004	Janssen Pharmaceutica N.V., Belg.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/048343	06-10-2004	Schering AG		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/046118	06-03-2004	Bayer Pharmaceuticals Corp.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/039359	05-13-2004	Bayer Pharmaceuticals Corp.		<input type="checkbox"/>	<input type="checkbox"/>
ICW		WO	2004/002964	01-08-2004	Yamanouchi Pharmaceutical Co.		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

*ve Wedderburn*

DATE CONSIDERED

8-18-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number	10/631,029	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Filing Date	July 29, 2003	
				First Named Inventor	Rajinder Singh	
				Art Unit	1632	
				Examiner Name	Unknown	
Sheet	2	of	2	Attorney Docket Number	28585/US/US	

#### FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
Ww		WO	03/094920	11-20-2003	Tibotec Pharmaceuticals		<input type="checkbox"/>	<input type="checkbox"/>
1		WO	03/045923	06-05-2003	Sankyo Company Limited		<input type="checkbox"/>	<input type="checkbox"/>
		WO	2004/074261	09-02-2004	Tibotec Pharmaceuticals		<input type="checkbox"/>	<input type="checkbox"/>
Ww		WO	2004/014382	02-19-2004	Rigel Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>

#### OTHER DOCUMENTS – NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	YES	NO
Ww		Cores: An Automated Method for Generating Three-Dimensional Models of Protein/Ligand Complexes, Hare, Brian J., Journal of Chemistry (2004)47(19), 4731-4740		<input type="checkbox"/>	<input type="checkbox"/>
		Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC 125-R165335 (Etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. Das, Kalyan; Journal of Medicinal Chemistry (2004), 47(10), 2550-2560		<input type="checkbox"/>	<input type="checkbox"/>
		Identification of Compounds with Nanomolar binding Affinity for Checkpoint Kinase-1 Using Knowledge-Based Virtual Screening. Lyne, Paul D.; Journal of Medicinal Chemistry (2004) 47(8), 1962-1968		<input type="checkbox"/>	<input type="checkbox"/>
Ww		Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimization of substituted 2,4-bis anilino pyrimidines. Bioorganic & Medicinal Chemistry Letters (2203), 13(18), 2961-2966		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE	Ww. <i>Wolchuk</i>	DATE CONSIDERED
--------------------	--------------------	-----------------

8-18-08

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SUBSTITUTE for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/631,029
Filing Date	July 29, 2003
First Named Inventor	Rajinder Singh
Art Unit	Unknown
Examiner Name	Unknown

Attorney Docket Number 28575/US/US

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number – Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number – Kind Code (if known)				YES	NO
llw		WO	00/59893	10/12/2000	Krenitsky Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS – NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
llw		"Synthesis and Antiinflammatory Properties of O-Carboxyphenylamino Pyrimidines", Kiev Scientific-Research Institute of Pharmacology and Toxicology, translated from Khimko-framatsevticheskii Zhurnal, Vol. 17, No. 11, pp. 1304-1307, November 1983, 1984 Plenum Publishing Corporation, pgs. 777-779, original article submitted January 12, 1983.	<input type="checkbox"/>	<input type="checkbox"/>
		"Chemistry of Heterocyclic Compounds, Vol. 2, No. 5, September –October 1966, The Faraday Press, Inc., pp. 606-611	<input type="checkbox"/>	<input type="checkbox"/>
		"SU Alcune 5-Fluoro-6-Anilino-Aminopirimidine", M.G. Biressi, G. Cantarelli, M. Carissimi, F. Ravenna, Bollettino Chimico Farmaceutico, 1966, Vol. 105, No. 9, pp. 660-665	<input type="checkbox"/>	<input type="checkbox"/>
		"Synthesis of 2,4-Disubstituted 5-Aminopyrimidine-6- Carboxylic Acids Derivatives Part I.", Polish Journal of Pharmacology and Pharmacy, Vol. 28, No. 1, 1976, pp. 61-67	<input type="checkbox"/>	<input type="checkbox"/>
llw		"Synthesis and Hypolipidemic Activity of 6-Alkyl (Aryl)Amino-2-Chloropyrimidine-4-Carboxylic Acid Esters", Chemija Chemistry, 1998, ISSN 0235-7216, pp. 90-92	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE llw

DATE CONSIDERED

8.18.05


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number	10/631,029
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Filing Date	July 29, 2003
				First Named Inventor	Rajinder Singh
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	2	Attorney Docket Number	28575/US/US

#### OTHER DOCUMENTS – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
10		“Chemotherapy for Onchocerciasis: Results of <i>in vitro</i> Experiments with Promising New Compounds”, Tropical Medicine and International Health, Vol. 3, No. 5, pp. 397-407, May 1998 Blackwell Science Ltd.	<input type="checkbox"/>	<input type="checkbox"/>
W		“Khimiko-Farmatsevticheskii Zhurnal”, 1983, Vol 11, pp. 1281-1282, 1304-1307	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE <i>UCU</i>	DATE CONSIDERED <i>8-18-05</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<p>Substitute for form 1449A/PTO</p> <p style="text-align: center;"><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(use as many sheets as necessary)</i></p>				
<p style="text-align: center;">U.S. PATENT &amp; TRADEMARK OFFICE</p>				
		Application Number	10/631,029	
		Filing Date	July 29, 2003	
		First Named Inventor	Rajinder Singh	
		Art Unit	Unknown	
		Examiner Name	Unknown	
Sheet	1	of	1	
			Attorney Docket Number	28560/US/3

## **OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

**EXAMINER SIGNATURE**

Woo

**DATE CONSIDERED**

8-15-05-

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 07 2004

PTO/SB/08A (10/01) (modified)  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

Application Number 10/631,029

Filing Date July 29, 2003

First Named Inventor Rajinder Singh

Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number 28575/US/US

## U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
W		US- 6,593,326	7/15/2003	Bradbury et al.	
		US- 6,579,983	6/17/2003	Batchelor	
		US- 6,528,513	3/4/2003	Cushing et al.	
		US- 6,525,051	2/25/2003	Davey et al.	
		US- 6,489,333	12/3/2002	Pitts et al.	
		US- 6,440,986	8/27/2002	Andries et al.	
		US- 6,432,963	8/13/2002	Hisamichi et al.	
		US- 6,372,751	4/16/2002	Davey et al.	
		US- 6,342,503	1/29/2002	Aldrich et al.	
		US- 6,337,335	1/8/2002	Hutchings et al.	
		US- 6,235,746	5/22/2001	Davis et al.	
		US- 6,200,977	3/13/2001	Cushing et al.	
		US- 6,197,779	3/6/2001	Andries et al.	
		US- 6,127,376	10/3/2000	Davey et al.	
		US- 6,080,858	6/27/2000	Schumacher	
		US- 6,048,866	4/11/2000	Hutchings et al.	
		US- 6,022,884	2/8/2000	Mantlo	
		US- 6,004,985	12/21/1999	Kochanny	
		US- 5,958,935	9/28/1999	Davis et al.	
		US- 5,863,924	1/26/1999	Berger et al.	
		US- 5,840,893	11/24/1998	Bukrinsky et al.	
		US- 5,585,381	12/17/1996	Yanaka et al.	
W		US- 5,521,184	5/28/1996	Zimmermann	

EXAMINER SIGNATURE

DATE CONSIDERED

8-18-08

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 07 2004

PTO/SB/08A (10/01) (modified)  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Semi-form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

7

Application Number 10/631,029

Filing Date July 29, 2003

First Name Inventor Rajinder Singh

Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number 28575/US/US

## U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
10		US- 5,420,129	5/30/1995	Breu	
		US- 5,223,505	6/29/1993	Hargreaves	
		US- 5,179,204	1/12/1993	Effland et al.	
		US- 5,147,876	9/15/1992	Mizuchi et al.	
		US- 4,983,608	1/8/1991	Effland et al.	
10		US- 3,159,547	12/1/1964	Hollis et al.	

## FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
10		WO	03/078404	9/25/2003	Novartis Pharma GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/074515	9/12/2003	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/066601	2/8/2002	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/062225	7/31/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/063794	8/7/2003	Rigel Pharmaceuticals Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/048133	6/12/2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/040141	5/15/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/032997	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/032994	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/030909	4/17/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026666	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026665	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026664	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
10		WO	03/018022	3/6/2003	Amgen Inc.		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE *vb*

DATE CONSIDERED

8-18-05-

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 07 2004

PTO/SB/08A (10/01) (modified)  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Subscribed for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 7

Application Number 10/631,029

Filing Date July 29, 2003

First Name &amp; Inventor Rajinder Singh

Art Unit Unknown

Examiner Name Unknown

Attorney Docket Number 28575/US/US

### FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION
RL		WO	03/018021	3/6/2003	Amgen Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/016306	2/27/2002	Janssen Pharmaceutica N.V.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/002544	1/9/2003	Bristol-Myers Squibb Company	<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/000186	1/3/2003	Ariad Pharmaceuticals Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/102313	12/27/2002	Bristol-Myers Squibb Company	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/066481	8/29/2002	Astrazeneca AB	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/066480	8/29/2002	Astrazeneca AB	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/066461	8/28/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/064096	8/22/2002	Tularik Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/062789	8/15/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/059112	8/1/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/059110	8/1/2002	Glaxo Group Limited	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/50066	6/27/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/45652	6/13/2002	Merck & Co. Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/22601	3/21/2002	Vertex Pharmaceuticals, Inc.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	02/04429	1/17/2002	Astrazeneca AB	<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/85700	11/15/2001	Janssen Pharmaceutica N.V.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/85699	11/15/2001	Janssen Pharmaceutica N.V.	<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/72744	10/4/2001	Schering Aktiengesellschaft	<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/64656	9/7/2001	Astrazeneca AB	<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/64654	9/7/2001	Astrazeneca AB	<input type="checkbox"/>	<input type="checkbox"/>
		WO	01/64655	9/7/2001	Astrazeneca UK Limited	<input type="checkbox"/>	<input type="checkbox"/>
RL		WO	00/63182	4/20/1999	Bayer Aktiengesellschaft	<input type="checkbox"/>	<input checked="" type="checkbox"/>

EXAMINER SIGNATURE

*Wes*

DATE CONSIDERED

8-18-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	7	Attorney Docket Number	28575/US/US
-------	---	----	---	------------------------	-------------

### FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cde No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
IC		WO	01/60816	8/23/2001	Amgen Inc.		<input type="checkbox"/> <input type="checkbox"/>
		WO	01/23389	5/2001	Neuro-Gen Corporation		<input type="checkbox"/> <input type="checkbox"/>
		WO	01/22938	4/5/2001	Janssen Pharmaceutica N.V.		<input type="checkbox"/> <input type="checkbox"/>
		WO	01/09134	2/8/2001	Novartis AG		<input type="checkbox"/> <input type="checkbox"/>
		WO	00/76980	12/21/2000	Yamanouchi Pharmaceutical Co., Ltd.		<input type="checkbox"/> <input type="checkbox"/>
		WO	00/78731	12/28/2000	Cell-Tech Chiroscience Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	00/39101	7/6/2000	Astrazeneca UK Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	00/33844	6/15/2000	Berlex Laboratories Inc.		<input type="checkbox"/> <input type="checkbox"/>
		WO	00/27826	5/18/2000	Boehringer Ingelheim Pharma KG		<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO	00/27825	5/18/2000	Janssen Pharmaceutica N.V.		<input type="checkbox"/> <input type="checkbox"/>
		WO	00/12485	3/9/2000	Zeneca Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	99/61437	12/2/1999	Smithkline Beecham Corporation		<input type="checkbox"/> <input type="checkbox"/>
		WO	99/50251	10/7/1999	Cancer Research Campaign Technology Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	99/50250	10/7/1999	Janssen Pharmaceutica N.V.		<input type="checkbox"/> <input type="checkbox"/>
		WO	99/50249	10/7/1999	Du Pont Pharmaceuticals Company		<input type="checkbox"/> <input type="checkbox"/>
		WO	99/41253	8/19/1999	Tularik Inc.		<input type="checkbox"/> <input type="checkbox"/>
		WO	99/31073	6/24/1999	Yamanouchi Pharmaceutical Co. Ltd.		<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO	99/24874	5/20/1999	Zeneca Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	98/41512	9/24/1998	Celltech Therapeutics Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	97/19065	5/29/1997	Celltech Therapeutics Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO	95/19358	7/20/1995	Sandoz-Patent GmbH		<input type="checkbox"/> <input type="checkbox"/>
IC		WO	91/18887	12/12/1991	Smith-Kline Beecham Intercredit B.V.		<input type="checkbox"/> <input type="checkbox"/>

EXAMINER SIGNATURE *Voe*

DATE CONSIDERED *8-18-08*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 07 2004

Safeguard Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 7

Application Number 10/631,029

Filing Date July 29, 2003

First Named Inventor Rajinder Singh

Art Unit Unknown

Examiner Name Unknown

Sh et 5 of 7 Attorney Docket Number 28575/US/US

**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cte No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
lw		WO	90/12790	11/1/1990	Imperial Chemical Industries PLC		<input type="checkbox"/> <input checked="" type="checkbox"/>
		DE	4029650 A1	3/26/1992	Hoeschst AG		<input type="checkbox"/> <input checked="" type="checkbox"/>
		AU	748087	8/30/1999	Tularik Inc.		<input type="checkbox"/> <input checked="" type="checkbox"/>
		EP	1 056 742 B1	12/6/2000	Tularik Inc.		<input type="checkbox"/> <input checked="" type="checkbox"/>
		EP	0525768	02/03/1993	J. Uriach & Cia. S.A.		<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO	01/47897	07/05/2001	Pharmacopeia, Inc.		<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO	00/58305	10/05/2001	Astrazeneca UK Limited		<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO	03/076437	09/18/2003	Schering AG		<input type="checkbox"/> <input checked="" type="checkbox"/>
llc		GB	2373186	09/18/2002	Astrazeneca AB		<input type="checkbox"/> <input checked="" type="checkbox"/>

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cte No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES <input type="checkbox"/>	NO <input checked="" type="checkbox"/>
ll		Radinov et al., Fiziologcheski Aktivnye Veshchestva 7:68-72 (1975)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Kuz'menko & Protsenko, Chemistry of Heterocyclic Compounds, pp. 105-107; English translation of Kuz'menko & Protsenko, Khimiya Geterotsiklicheskikh Soedinenii 1:117-119 (1975)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		N2,N4-Bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0026	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		N2,N4-Bis(2-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0031	<input type="checkbox"/>	<input checked="" type="checkbox"/>
ll		N2,N4-Bis(4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0003	<input type="checkbox"/>	<input checked="" type="checkbox"/>

EXAMINER SIGNATURE Ugo Uffo

DATE CONSIDERED 8-18-05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

6 of 7

Application Number	10/631,029
Filing Date	July 29, 2003
First Named Inventor	Rajinder Singh
Art Unit	Unknown
Examiner Name	Unknown

Attorney Docket Number 28575/US/US

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

<i>(initials)</i>	N2,N4-Bis(3-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0021	<input type="checkbox"/>	<input type="checkbox"/>
	N2,N4-Bis(2,5-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0024	<input type="checkbox"/>	<input type="checkbox"/>
	N2,N4-Bis(3,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0027	<input type="checkbox"/>	<input type="checkbox"/>
	N2,N4-Bis(4-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0005	<input type="checkbox"/>	<input type="checkbox"/>
	N2,N4-Bis(2,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0035	<input type="checkbox"/>	<input type="checkbox"/>
	N2,N4-Bis(3-bromophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0059	<input type="checkbox"/>	<input type="checkbox"/>
	N2-(4-hydroxyphenyl)-N4-(4-methoxyphenyl)-6-methyl-2,4-diaminopyrimidine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1079-1249	<input type="checkbox"/>	<input type="checkbox"/>
	4-methyl-N-(4-t-butylphenyl)-6-(3,5-dimethylpyrazole)-2,pyrimidinamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #0122-0021	<input type="checkbox"/>	<input type="checkbox"/>
	N2,N4-Bis(4-hydroxy-2-methylphenyl)-6-methyl-5-nitro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #0781-2697	<input type="checkbox"/>	<input type="checkbox"/>
	6-(t-butyl)-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #GK 01685	<input type="checkbox"/>	<input type="checkbox"/>
	5-[(4-chlorophenyl)sulfonyl]-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #KM 00680	<input type="checkbox"/>	<input type="checkbox"/>
<i>(initials)</i>	6-(4-chlorophenyl)-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #GK 01237	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE *[Signature]*DATE CONSIDERED *8-18-05*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 07 2004

PTO/SB/08A (10/01) (modified)  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Standard Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	7	of	7	Attorney Docket Number	28575/US/US
-------	---	----	---	------------------------	-------------

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
ll		N1-[2-amino-6-(4-fluoromethyl)pyrimidin-4-yl]-4-(trifluoromethyl)benzene-1-sulfonamide, commercially available from Maybridge, Cornwall, ENGLAND, catalog #GK 01714	<input type="checkbox"/>	<input type="checkbox"/>
		N4-(2,4-difluorophenyl)-6-methyl-2,4-pyrimidinediamine hydrochloride, commercially available from Maybridge, Cornwall, ENGLAND, catalog #RJF 00403	<input type="checkbox"/>	<input type="checkbox"/>
		N4-(3-pyridylmethyl)-6-methyl-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #RDR 02058		
		N4-[(3,4-dimethoxyphenyl)ethyl]-6-methyl-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #RDR 02059		
		N2,N4-Bisphenyl-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0033	<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(3-methylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0013	<input type="checkbox"/>	<input type="checkbox"/>
ll		N2,N4-Bis(2-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0007	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

8-15-08

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.